Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00033904 | Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer | PHASE3 | COMPLETED | 650 | — | — | Jun 1, 2000 | Apr 1, 2007 | Sep 7, 2012 | 76 | United States, Austria +9 |
| Name | Type | Description |
|---|---|---|
| autologous human tumor-derived HSPPC-96 | DRUG | - |
Pre-Surgery Inclusion Criteria: * Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent; * Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluatio...